Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on Airbus Group SE (EADSF – Research Report) and Equifax ...
Zacks.com on MSN5d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
Shares of Equifax Inc. EFX shed 2.64% to $267.52 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...
We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback